Effects of dietary methionine and cysteine restriction on plasma biomarkers, serum fibroblast growth factor 21, and adipose tissue gene expression in women with overweight or obesity: a double-blind randomized controlled pilot study
Contamination due to alternative weight loss intervention (Intervention and control) Since semaglutide was first licenced for the treatment of obesity in 2021, tirzepatide, a GLP-1/GIP receptor agonist with has even greater efficacy of weight loss, has achieved FDA approval in 2023
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
These findings support a meaningful role for these medications in blood pressure management in overweight and obesity and underscore the need for targeted mechanistic and clinical studies to calculate weight-dependent and weight-independent effects, they added
The standardized instruments and tests were performed identically in ALS-cases and controls
